Refine by
Coronavirus Covid Articles & Analysis
48 news found
Viral Vaccine Manufacturing to control pandemics: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) has created a global public health crisis. ...
ByNuvonis
Hospitals treating COVID-19 patients are looking to use the radar-based technology, previously used in heart-failure patients, to monitor lungs of coronavirus patients. Sensible Medical has recently received urgent requests from hospitals around the world for its ReDS monitors systems to improve monitoring, treatment and resource use for ...
Food and Drug Administrations (‘FDA’) for development of its lead antiviral drug BIT225 as a potential treatment of Coronavirus Disease 2019 (COVID-19) infection in adults. The FDA’s guidance was received in written response to Biotron’s pre-IND briefing package and request in March 2022, which included an overview of preclinical and ...
Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible effects on our operations, and the demand for our products; our ability to successfully ...
COVID-19 and seasonal allergies have many of the same signs and symptoms. ...
(POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing pandemic crisis caused by Severe Acute Respiratory ...
Executive Summary: At this time all Brentwood sites are operational. Our Indian facility reopened production this week, following a shutdown that was mandated by the Indian government. Our workforce is committed to continued support of our customers during the COVID-19 outbreak and our supply stream remains strong. As always we will get through this today, tomorrow, and ...
Food and Drug Administration (FDA) for a Phase 1 clinical study of MV-014-212, the company’s intranasal live attenuated chimeric vaccine candidate against SARS-CoV-2, the coronavirus that causes COVID-19. MV-014-212 offers significant potential advantages for COVID-19 vaccine global deployment, including needle-free intranasal ...
Environmental Protection Agency’s (EPA) Office of Enforcement and Compliance Assurance (OECA) announced that it issued a revised compliance advisory (Advisory) on products claiming to kill SARS-CoV-2, the novel coronavirus that causes COVID-19. EPA first issued this guidance on June 1, 2020, and it is discussed in our blog here. ...
The British Occupational Hygiene Society, a scientific charity and the Chartered Society for Worker Health Protection is issuing the following guidance on the mutations emerging to COVID-19 virus. Surveillance on mutations occurring in the COVID-19 virus has reported a number of mutations Data – COG-UK Consortium (cogconsortium.uk). ...
” If the approach can be proved further, it could make clinical research more efficient and value driven in elucidating other rare or novel diseases like coronavirus disease (COVID-19) with smaller patient populations. “Our research related to the coronavirus is in many ways a metaphor for all of our AI work, where one clinical ...
This announcement follows up on EPA’s October 14, 2020, announcement that it would begin expediting its review of products with residual efficacy intended for use against SARS-CoV-2, the coronavirus that causes COVID-19. While traditional disinfectants only kill viruses and bacteria that are on the surface at the time they are used, surfaces treated with ...
Environmental Protection Agency (EPA) released much-anticipated draft guidance that will allow companies to demonstrate that their products have “long-lasting” or “residual” effectiveness on surfaces against viruses like SARS-CoV-2, the coronavirus that causes COVID-19. As most know, EPA has not before now provided guidance on how ...
These are unprecedented times with the global outbreak of Coronavirus (COVID-19). We want our customers, partners, suppliers, employees and community to know that Anguil is following an existing, robust, business continuity plan for managing situations such as this. ...
This adds to a full line of top-quality Plexiglass Partitions and other isolation barriers to meet the needs of all industries to protect workers, customers and visitors and stop the spread of the Coronavirus. The Accu-Shield SG Clear Barrier Panels provide sneeze guard style protection through-out work areas in offices, warehouses and commercial settings with unobstructed ...
Environmental Protection Agency (EPA) announced that EPA researchers are evaluating a number of commercially available products for potential long-lasting effectiveness against SARS-CoV-2, the novel human coronavirus that causes COVID-19. This research is being conducted at EPA’s Office of Research and Development's Center for Environmental Solutions and ...
Food and Drug Administration (FDA) for the development of MV-014-210, a live attenuated vaccine (LAV) candidate to induce immunity and protect against SARS-CoV-2, the novel coronavirus that causes COVID-19. Meissa also announced today interim results from the first-in-human study of MV-012-968, the company’s LAV candidate for respiratory syncytial virus ...
Environmental Protection Agency’s (EPA) Office of Enforcement and Compliance Assurance (OECA) announced that it issued a compliance advisory on products claiming to kill SARS-CoV-2, the novel coronavirus that causes COVID-19. EPA states that the advisory was issued because it has received tips and complaints concerning potentially false or misleading ...
Following the development of the spread of the Coronavirus COVID-19, we inform our customers that we are operating in compliance with the regulations and dispositions issued by the Italian Government. ...
Dilon Technologies’ CoPilot VL+ video laryngoscopy system provides an excellent tool for intubating patients, especially those with suspected Covid-19 Coronavirus. The system’s handle and video monitor are separated by a five-foot cord allowing the monitor to be positioned at eye level, providing a clear visualization of the vocal cords while allowing ...